OTTAWA, Oct. 16, 2015 /CNW/ - Annidis Corporation (TSX Venture: RHA) ("Annidis" or the "Company") announces that, subject to the final approval of the TSX Venture Exchange, it has granted incentive stock options to certain directors, officers and employees of Annidis for the purchase up to an aggregate of 2,500,000 common shares in the capital stock of Annidis. The options are exercisable at a price of $0.20 per common share and expire on October 16, 2020.
About Annidis Corporation
Annidis (TSX-V: RHA) has developed and is marketing a new imaging platform technology based on Multi-Spectral Imaging (MSI). This new technology is opening a new frontier in disease identification and its management. The Annidis MSI technology allows eye-care professionals to view non-invasively the deepest areas of the eye aiding eye care professionals in the early identification and treatment of debilitating eye diseases. The Corporation's existing RHA 2020-U Gold, used by eye care professionals as a broad based tool for detecting early-onset of eye related diseases such as Dry AMD, has a potential market of over 20,000 clinics in North America. The RHA Platinum MD will further strengthen the value proposition allowing doctors to visualize choroidal and retinal vasculature non-invasively. The RHA Platinum MD has global market potential of more than 100,000 Ophthalmologists.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE Annidis Corporation
For further information: Michael Crowley, CEO, Annidis Corporation, 519-859-7439, firstname.lastname@example.org; Babak Pedram, Investor Relations, Virtus Advisory Group Inc., 416-995-8651, email@example.com